絞り込み

16645

広告

Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.

著者 Locatelli F , Mauz-Koerholz C , Neville K , Llort A , Beishuizen A , Daw S , Pillon M , Aladjidi N , Klingebiel T , Landman-Parker J , Medina-Sanson A , August K , Sachs J , Hoffman K , Kinley J , Song S , Song G , Zhang S , Suri A , Gore L
Lancet Haematol.2018 Oct ; 5(10):e450-e461.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (7view , 1users)

Full Text Sources

Medical

Despite remarkable progress in the treatment of newly-diagnosed classical Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma, treatment of relapsed or refractory disease remains challenging. The aims of this study were to assess the safety, tolerability, recommended phase 2 dose, and efficacy of brentuximab vedotin in paediatric patients with relapsed or refractory Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma.
PMID: 30290902 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード